Alnylam Pharmaceuticals, Inc. (ALNY)

NASDAQ: ALNY · Real-Time Price · USD

320.42

+1.51 (0.47%)

At close: Mar 17, 2026, 4:00 PM EDT

316.46

-3.96 (-1.24%)

After-hours: Mar 17, 2026, 6:19 PM EDT

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
AMVUTTRA Revenue	2.31B	970.45M
AMVUTTRA Revenue Growth	138.43%	73.97%
ONPATTRO Revenue	172.79M	252.86M
ONPATTRO Revenue Growth	-31.66%	-28.68%
GIVLAARI Revenue	308.49M	255.87M
GIVLAARI Revenue Growth	20.56%	16.70%
OXLUMO Revenue	191.44M	167.05M
OXLUMO Revenue Growth	14.60%	52.09%
Total Product Revenue	2.99B	1.65B
Total Product Revenue Growth	81.42%	32.60%
Roche - Collaboration Revenue	394.88M	119.49M
Roche - Collaboration Revenue Growth	230.47%	-64.63%
Regeneron Pharmaceuticals - Collaboration Revenue	113.96M	302.80M
Regeneron Pharmaceuticals - Collaboration Revenue Growth	-62.37%	201.39%
Novartis AG - Collaboration Revenue	-	79.76M
Novartis AG - Collaboration Revenue Growth	-	-8.03%
Other - Collaboration Revenue (Post-FY2022)	44.53M	8.18M
Other - Collaboration Revenue (Post-FY2022) Growth	444.69%	-61.42%
Total Collaboration Revenue	553.37M	510.22M
Total Collaboration Revenue Growth	8.46%	-6.59%
Royalty Revenue	174.02M	91.79M
Royalty Revenue Growth	89.58%	125.91%
Revenue (Other)	-553.37M	-510.22M
Revenue (Total)	3.71B	2.25B
Revenue (Total) Growth	65.19%	22.97%

Updated Feb 12, 2026. Data Source: Fiscal.ai.